



Plenary sitting

B8-0014/2017

3.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure

on the treatment of Crohn's disease

Mireille D'Ornano

Motion for a European Parliament resolution on the treatment of Crohn's disease

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
 - A. whereas Crohn's disease is an inflammatory bowel disease resulting essentially in abdominal pain and chronic digestive disorders which is particularly prevalent in the industrialised countries, and particularly in Western Europe – in Sweden, for instance, there are as many as 213 cases per 100 000 inhabitants;
 - B. whereas the causes of Crohn's disease are unknown, but smoking, vitamin D deficiency, pollutants and diet seem to help activate the genetic factors involved in the outbreak of this disease;
 - C. whereas, according to a study published on 16 October 2016, the mongersen experimental drug (GED-0301, Celgene) seems to have resulted in a remission of the disease among almost half of patients after twelve months of treatment (160 mg per day);
 - 1. Encourages the Commission to support research and facilitate the marketing, if necessary, of a treatment for Crohn's disease.